Navigation Links
NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
Date:6/1/2009

    - Results from a randomized Phase IIb trial reported at 2009 ASCO Annual
    Meeting -

MISSISSAUGA, ON, June 1 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that results from a randomized trial of nimotuzumab (aka BIOMAb/TheraCIM/h-R3) in patients with inoperable, locoregionally advanced Stage III/IVa head and neck cancer conducted by Reddy BK et al (Kidwai Memorial Institute of Oncology, Bangalore, India), were presented in a poster at the 2009 ASCO Annual Meeting. The trial demonstrates that the efficacy of nimotuzumab compares favorably to results reported for cetuximab, an EGFR-targeting antibody marketed as Erbitux(R), but that this efficacy was not accompanied by the severe toxicities reported in patients treated with cetuximab. The authors further conclude that this trial is the first randomized study in head and neck cancer to their knowledge that challenges the adopted tenet that the efficacy of EGFR inhibitors is linked to the toxicity of the class.

"These data are further evidence of the unsupported extrapolation to the class of the toxicity/benefit correlation in the marketed EGFR drugs. The trial data demonstrate that patients have the prospect of equivalent clinical benefit from nimotuzumab as from the rest of the class without the physical, emotional and financial costs that result from the numerous and severe toxicities of Erbitux(R) which are a consequence of the demonstrable inability of that drug to discriminate between healthy cells and tumor cells," said David Allan, Chairman and CEO of YM BioSciences. "We expect that, as the numerous randomized trials currently ongoing worldwide with nimotuzumab re
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
2. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
3. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
4. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
5. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
6. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
7. NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
8. NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER
9. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
10. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
11. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 On Friday, December 19, ... the Omnibus and Continuing Resolution Appropriations Act of ... a condition eligible to receive funding through the ... the Department of Defense (DoD). The Hydrocephalus Association ... Capitol Hill, is celebrating this victory for the ...
(Date:12/24/2014)... 2014 The report expects global cell ... 2019. It also provides a carefully analyzed data about ... for the market. , Full Copy of Report @ ... global market for cell expansion will keep witnessing growth ... this growth to be driven by rapid technological advancements, ...
(Date:12/24/2014)... December 23, 2014 PharmaBoardroom,s ... out today and available for free download , digs ... change and growth in the sector today. One ... successes has been in developing a homegrown pharmaceutical manufacturing base, ... production still remains some way off. A cursory comparison with ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The ... global leader of technical training across the life sciences ... Data Management (SCDM) to provide the organization's members ... programs —providing access to the more than 350 sessions ... members with 10% off when registering for a ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... US Oncology, Inc ., the nation,s ... treatment and research network in the United States, ... quarter of fiscal 2010 on Thursday, Nov. 4. ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20100517/DA06089LOGO ) A conference ...
... HONG KONG, Oct. 7 /PRNewswire-Asia-FirstCall/ -- China Cord ... CO ), the first and largest cord blood ... authorization of the stock repurchase program on September 15, ... for approximately US$1.6 million through October 6, 2010 at ...
... Dendreon Corporation (Nasdaq: DNDN ) today announced ... 3, 2010 at 4:30 p.m. ET to review third quarter ... be obtained as follows: Time: , 4:30 PM ... 2010Dial-in: , 1-866-730-5769 (domestic) or +1-857-350-1593 (international); conference ...
Cached Biology Technology:US Oncology to Report 2010 Third Quarter Operating Results 2China Cord Blood Corporation Updates Status Regarding Share Repurchase Program 2Dendreon to Host Conference Call on November 3rd to Announce Third Quarter Financial Results 2
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin ... deployed, innovative test solutions for military, aerospace, and ... version of its successful TS-900 PXI semiconductor ... and features of high-end systems to customers at ... value compared to traditional ATE. ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... linked to many of the same health problems as tobacco ... wheeze, according to a new study by researchers at Yale ... used illicit drug in the United States, and abuse of ... in today's Archives of Internal Medicine. First author Jeanette M. ...
... of the same health problems as tobacco smoke, such as ... a new study by researchers at Yale School of Medicine. ... in the United States, and abuse of the drug is ... of Internal Medicine. First author Jeanette M. Tetrault, M.D., and ...
... has long been recognized that birds possess the ability to ... how this is done has not yet been clarified. ... homing pigeons in a new study (1) by Gerta Fleissner ... promising insight into this complex topic. The article will ...
Cached Biology News:Migration played key role in HIV spread in South Africa 2Long-term marijuana smoking leads to respiratory complaints 2Homing pigeons get their bearings from their beaks 2
Request Info...
... RNA polymerase is a DNA-dependent RNA polymerase ... promoters. It efficiently synthesizes in vitro ... down stream from a T7 promoter. ... templates for in vitro translation, substrates in ...
... yeast/leuconostoc overproducer ATP: D-hexose 6- ... One unit of HK will ... in 1 min at 25C ... of G6P-DH will oxidize 1 ...
... H degrades, as an endoribonuclease, the ... hybrids of natural origin, e.g. that ... complexes, e.g. poly(A) x poly(dT). RNase ... 3-OH termini. Nearly no activity is ...
Biology Products: